WO2005016371A8 - IMPROVED RECOMBINANT HUMAN INTERFERON-BETA-1b POLYPEPTIDES - Google Patents

IMPROVED RECOMBINANT HUMAN INTERFERON-BETA-1b POLYPEPTIDES

Info

Publication number
WO2005016371A8
WO2005016371A8 PCT/US2004/021618 US2004021618W WO2005016371A8 WO 2005016371 A8 WO2005016371 A8 WO 2005016371A8 US 2004021618 W US2004021618 W US 2004021618W WO 2005016371 A8 WO2005016371 A8 WO 2005016371A8
Authority
WO
WIPO (PCT)
Prior art keywords
beta
polypeptides
recombinant human
human interferon
ifn
Prior art date
Application number
PCT/US2004/021618
Other languages
French (fr)
Other versions
WO2005016371A1 (en
Inventor
Eirik Nestaas
Erno Pungor
Original Assignee
Schering Ag
Eirik Nestaas
Erno Pungor
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AU2004264855A priority Critical patent/AU2004264855A1/en
Priority to JP2006518844A priority patent/JP2007530419A/en
Priority to ES04777620T priority patent/ES2393783T3/en
Priority to EP04777620A priority patent/EP1646397B1/en
Priority to CA002528514A priority patent/CA2528514A1/en
Priority to MXPA06000460A priority patent/MXPA06000460A/en
Application filed by Schering Ag, Eirik Nestaas, Erno Pungor filed Critical Schering Ag
Priority to BRPI0412477-4A priority patent/BRPI0412477A/en
Publication of WO2005016371A1 publication Critical patent/WO2005016371A1/en
Priority to IL172269A priority patent/IL172269A0/en
Priority to NO20060675A priority patent/NO20060675L/en
Publication of WO2005016371A8 publication Critical patent/WO2005016371A8/en
Priority to IL207422A priority patent/IL207422A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The present invention relates to recombinant human interferon-beta-1b (“IFN-beta-1b”) polypeptides, or fragments analogs, derivatives, or variants thereof, having an improved specific activity. The present invention also relates to pharmaceutical compositions comprising such IFN-beta-1b polypeptides. or fragments, analogs, derivatives, or variants therof, useful for treating multiples sclerosis. The present invention further relates to methods of producing such IFN-beta-1b compositions.
PCT/US2004/021618 2003-07-11 2004-07-06 IMPROVED RECOMBINANT HUMAN INTERFERON-BETA-1b POLYPEPTIDES WO2005016371A1 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
JP2006518844A JP2007530419A (en) 2003-07-11 2004-07-06 Improved recombinant human interferon-beta-1b polypeptide
ES04777620T ES2393783T3 (en) 2003-07-11 2004-07-06 Enhanced recombinant human interferon-beta-1b polypeptides
EP04777620A EP1646397B1 (en) 2003-07-11 2004-07-06 IMPROVED RECOMBINANT HUMAN INTERFERON-BETA-1b POLYPEPTIDES
CA002528514A CA2528514A1 (en) 2003-07-11 2004-07-06 Improved recombinant human interferon-beta-1b polypeptides
MXPA06000460A MXPA06000460A (en) 2003-07-11 2004-07-06 IMPROVED RECOMBINANT HUMAN INTERFERON-BETA-1b POLYPEPTIDES.
AU2004264855A AU2004264855A1 (en) 2003-07-11 2004-07-06 Improved recombinant human interferon-beta-1b polypeptides
BRPI0412477-4A BRPI0412477A (en) 2003-07-11 2004-07-06 recombinant human interferon-beta-1b polypeptides improved
IL172269A IL172269A0 (en) 2003-07-11 2005-11-30 Improved recombinant human interferon-beta-ib polypeptides
NO20060675A NO20060675L (en) 2003-07-11 2006-02-10 Enhanced recombinant human interferon beta-lb polypeptides
IL207422A IL207422A0 (en) 2003-07-11 2010-08-05 Improved recombinant human interferon-beta-ib polypeptides

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48665703P 2003-07-11 2003-07-11
US60/486,657 2003-07-11

Publications (2)

Publication Number Publication Date
WO2005016371A1 WO2005016371A1 (en) 2005-02-24
WO2005016371A8 true WO2005016371A8 (en) 2006-06-15

Family

ID=34193062

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/021618 WO2005016371A1 (en) 2003-07-11 2004-07-06 IMPROVED RECOMBINANT HUMAN INTERFERON-BETA-1b POLYPEPTIDES

Country Status (15)

Country Link
US (1) US20050008616A1 (en)
EP (1) EP1646397B1 (en)
JP (1) JP2007530419A (en)
KR (1) KR20060034286A (en)
CN (1) CN100408090C (en)
AU (1) AU2004264855A1 (en)
BR (1) BRPI0412477A (en)
CA (1) CA2528514A1 (en)
ES (1) ES2393783T3 (en)
IL (2) IL172269A0 (en)
MX (1) MXPA06000460A (en)
NO (1) NO20060675L (en)
RU (1) RU2006104023A (en)
WO (1) WO2005016371A1 (en)
ZA (1) ZA200601236B (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2573113A1 (en) * 2004-07-26 2006-02-09 Enzon Pharmaceuticals, Inc. Optimized interferon-beta gene
EP1909822B1 (en) 2005-06-29 2013-09-25 Yeda Research And Development Co., Ltd. Recombinant interferon alpha 2 (ifn alpha 2) mutants
WO2008137471A2 (en) 2007-05-02 2008-11-13 Ambrx, Inc. Modified interferon beta polypeptides and their uses
CA2707840A1 (en) 2007-08-20 2009-02-26 Allozyne, Inc. Amino acid substituted molecules
WO2009045553A1 (en) * 2007-10-05 2009-04-09 Barofold, Inc. High pressure treatment of aggregated interferons
CN103898123B (en) * 2012-12-28 2019-03-15 北京韩美药品有限公司 Recombined human IFN-β -1a and its production and purification process
CN108841793B (en) * 2018-06-08 2021-08-27 东北农业大学 Anti-duck Mx-A monoclonal antibody and application thereof in detection of duck Mx protein

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5326859A (en) 1979-10-30 1994-07-05 Juridical Foundation, Japanese Foundation For Cancer Research DNA and recombinant plasmid
US4588585A (en) * 1982-10-19 1986-05-13 Cetus Corporation Human recombinant cysteine depleted interferon-β muteins
IL90047A (en) * 1982-10-19 1992-12-01 Cetus Oncology Corp Cysteine-depleted biologically active muteins other than interferon - '
US4530787A (en) 1984-03-28 1985-07-23 Cetus Corporation Controlled oxidation of microbially produced cysteine-containing proteins
US4572798A (en) * 1984-12-06 1986-02-25 Cetus Corporation Method for promoting disulfide bond formation in recombinant proteins
US5814485A (en) 1995-06-06 1998-09-29 Chiron Corporation Production of interferon-β (IFN-β) in E. coli
UY27373A1 (en) * 2001-07-09 2003-02-28 Schering Ag BETA-HUMAN INTERFER FORMULATIONS

Also Published As

Publication number Publication date
US20050008616A1 (en) 2005-01-13
RU2006104023A (en) 2006-07-27
AU2004264855A1 (en) 2005-02-24
EP1646397B1 (en) 2012-08-22
NO20060675L (en) 2006-04-06
CN100408090C (en) 2008-08-06
CA2528514A1 (en) 2005-02-24
IL207422A0 (en) 2010-12-30
ES2393783T3 (en) 2012-12-28
IL172269A0 (en) 2006-04-10
MXPA06000460A (en) 2006-04-07
EP1646397A1 (en) 2006-04-19
JP2007530419A (en) 2007-11-01
CN1822852A (en) 2006-08-23
WO2005016371A1 (en) 2005-02-24
BRPI0412477A (en) 2006-09-19
KR20060034286A (en) 2006-04-21
ZA200601236B (en) 2007-05-30

Similar Documents

Publication Publication Date Title
AU2003275958A1 (en) Muteins of tear lipocalin
WO2004047728A3 (en) Compositions and methods for the treatment of immune related diseases
WO2004039956A3 (en) Compositions and methods for the treatment of immune related diseases
MY140710A (en) Novel peptides as ns3-serine protease inhibitors of hepatitis c virus
TWI265927B (en) Novel compounds as NS3-serine protease inhibitors of hepatitis C virus
WO2005016962A3 (en) Compositions and methods for the treatment of immune related diseases
DE60110054D1 (en) Cardioprotektive phosphonate
IL232501A (en) Proteinase-resistant analogs of peptide or polypeptide and uses thereof
WO2002008244A3 (en) Peptides as ns3-serine protease inhibitors of hepatitis c virus
WO2005012242A3 (en) Substituted benzimidazole-, benztriazole-, and benzimidazolone-o-glucosides
MXPA05010682A (en) Novel compounds.
WO2004024097A8 (en) Compositions and methods for the treatment of immune related diseases
WO2004014322A3 (en) Immunomodulatory compositions, methods of making, and methods of use thereof
WO2006034154A3 (en) Salts of 5-azacytidine
WO2005033099A3 (en) Novel dipeptidyl peptidase iv inhibitors; processes for their preparation and compositions thereof
MY141528A (en) Anilinopyrazole derivatives useful for the treatment of diabetes
IL160171A0 (en) Depsipeptide derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
WO2005063764A3 (en) Fused pyrrolocarbazoles and methods for the preparation thereof
WO2003087062A3 (en) 4-(heterocyclyl)-benzenesulfoximine compounds for the treatment of inflammation
WO2003057149A3 (en) 4-substituted fused heteropyrimidines and fused hetero-4-pyrimidones
NO20060675L (en) Enhanced recombinant human interferon beta-lb polypeptides
AU2003260436A1 (en) Pyrimidine compounds
WO2004024072A3 (en) Novel compositions and methods for the treatment of immune related diseases
HK1121670A1 (en) Preparation and composition of inter-alpha inhibitor proteins from human plasma for therapeutic use
WO2002070001A3 (en) Use of lp82 to treat hematopoietic disorders

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200480019914.7

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 172269

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 5566/DELNP/2005

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2528514

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 544284

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 12006500091

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 1020067000638

Country of ref document: KR

Ref document number: 2006518844

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: PA/a/2006/000460

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2004777620

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2006/01236

Country of ref document: ZA

Ref document number: 2004264855

Country of ref document: AU

Ref document number: 200601236

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2006104023

Country of ref document: RU

ENP Entry into the national phase

Ref document number: 2004264855

Country of ref document: AU

Date of ref document: 20040706

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004264855

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2004777620

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020067000638

Country of ref document: KR

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 08/2005 UNDER (72, 75) REPLACE "NESTASS, EIRIK" BY "NESTAAS, EIRIK"

ENP Entry into the national phase

Ref document number: PI0412477

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: 207422

Country of ref document: IL